Myou S, Fujimura M, Kamio Y, Kita T, Katayama N, Abo M, Yoshimi Y, Nishitsuji M, Nomura S, Hashimoto T, Nakao S
The Third Department of Internal Medicine, Kanazawa University School of Medicine, Kanazawa, Japan.
Prostaglandins Leukot Essent Fatty Acids. 2001 Jul;65(1):41-4. doi: 10.1054/plef.2001.0286.
Acetaldehyde is a main factor of alcohol-induced asthma. We previously reported that the cysteinyl leukotriene (cys-LT) receptor antagonist, pranlukast hydrate, inhibits acetaldehyde-induced airway hyperresponsiveness in guinea pigs. The purpose of this study was to evaluate the involvement of cys-LT on bronchial responsiveness to acetaldehyde in asthmatic patients. We investigated the bronchial response to inhalation of acetaldehyde in 10 asthmatic patients, who were treated with placebo or pranlukast hydrate (225.5 mg), a cys-LT receptor antagonist, twice a day for 1 wk using a double-blind, randomized, placebo-controlled, cross-over design. Although a remarkable improvement of acetaldehyde bronchoconstriction was observed in 3 out of 10 subjects, PC(20)-AcCHO values were identical between placebo [12.0 (GSEM, 1.192) mg/ml] and pranlukast [14.7 (GSEM, 1.245) mg/ml] groups. The changes in bronchial responsiveness to acetaldehyde were similar in the six patients who had never experienced alcohol-induced asthma and the four who had. In conclusion, cys-LTs are not involved in acetaldehyde-induced bronchoconstriction.
乙醛是酒精诱发哮喘的主要因素。我们之前报道过，半胱氨酰白三烯（cys-LT）受体拮抗剂水合普仑司特可抑制豚鼠体内乙醛诱发的气道高反应性。本研究的目的是评估cys-LT在哮喘患者支气管对乙醛反应性中的作用。我们采用双盲、随机、安慰剂对照、交叉设计，对10名哮喘患者吸入乙醛后的支气管反应进行了研究，这些患者分别接受安慰剂或cys-LT受体拮抗剂水合普仑司特（225.5毫克）治疗，每日两次，持续1周。尽管10名受试者中有3名乙醛支气管收缩有显著改善，但安慰剂组[12.0（GSEM，1.192）毫克/毫升]和普仑司特组[14.7（GSEM，1.245）毫克/毫升]的PC(20)-AcCHO值相同。从未经历过酒精诱发哮喘的6名患者和经历过的4名患者对乙醛的支气管反应性变化相似。总之，cys-LT不参与乙醛诱发的支气管收缩。
